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A POTENTIAL TOLEROGENEIC ROLE OF SKIN GRAFTS IN PREVIOUSLY 
TOLERANT ANIMALS 
Joshua Weiner, Kazuhiko Yamada, Joseph Scalea, Yoshinori Ishikawa, Masayoshi 
Okumi, Adam Griesemer, Atsushi Hirakata, Justin Etter, Akira Shimizu, and David H. 
Sachs.  Transplantation Biology Research Center, Massachusetts General Hospital, 
Harvard Medical School, Boston, MA.  (Sponsored by Sukru H. Emre, Department of 
Surgery, Section of Transplantation and Immunology, Yale University School of 
Medicine). 
 
We have previously shown that long-term tolerance to class I disparate renal allografts in 
miniature swine is induced by a short course of Cyclosporine A (CyA). In these tolerant 
animals (TOL), the tolerance has been shown to involve T regulatory cells (Treg) and to 
persist for 3 to 4 months after the graft is removed. Naïve animals can be sensitized to 
major histocompatibility complex (MHC) class I mismatched renal allografts by 
inoculation with either class I peptide or by a donor-type skin graft. Six weeks after 
graftectomy, peptide immunization similarly sensitized TOL swine, but challenge with 
donor skin failed to sensitize (n=3). In this study, we further investigated the 
tolerogenicity of skin grafts under these conditions by challenging simultaneously with 
peptide and skin graft.  
 
Miniature swine underwent bilateral nephrectomy and MHC class I mismatched renal 
transplantation with a 12-day course of CyA to induce tolerance. 100 days after 
transplantation, graftectomy was performed and recipient-matched kidneys transplanted. 
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Six weeks later, pigs were simultaneously challenged with donor-type class I peptide and 
donor-type skin grafts. The effect on in vitro and in vivo immunity was determined.  
 
In contrast to animals treated only with peptide, all of which were sensitized to 2
nd
 renal 
allografts (rejection in 4-6 days) and developed strong anti-donor cellular and antibody 
responses (n=3), 2/5 recipients showed only a transient anti-donor cellular response and 
no or little anti-donor antibody production and maintained their second donor-type class I 
mismatched renal allografts long-term with normal creatinine. An additional animal 
experienced prolonged survival (11 days), and the final 2 animals rejected within 5-7 
days. Challenging with second donor-type skin grafts and third party skin graft indicated 
that hyporesponsiveness to the donor was specific.  
 
In animals tolerant of a class I mismatched renal allograft, which would be expected to be 
sensitized by class I peptide (indirect pathway of sensitization) at 6 weeks after 
graftectomy, a simultaneous donor-matched skin graft appeared to prevent sensitization 
in 2 of 5 and prolong survival in a third. These data are consistent with expansion of Treg 
following a class I mismatched skin graft, presumably by the direct pathway of activation. 
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I. Introduction 
 
Background: The Importance of Tolerance 
Despite the enormous progress which immunosuppressive drugs have permitted in the 
field of transplantation, there are also major drawbacks to these drugs.  All such agents 
cause nonspecific suppression of the immune system, which must be balanced to avoid 
rejection but not completely eliminate immune function.  Patients must then stay on 
chronic immunosuppressive therapy for the remainder of their lives, facing the major 
complications of too much or too little immunosuppression, including infection and 
rejection respectively as well as post-transplant lymph proliferative disorders (PTLD), 
direct toxicity of immunosuppressant medications, diabetes, and other metabolic 
derangements. 
 
Therefore, the induction of tolerance remains a major goal of transplantation immunology. 
Tolerance has various definitions. The most basic definition of tolerance is acceptance of 
a graft without immunosuppression, and “immune tolerance” denotes donor-specific 
hyporesponsiveness in vitro. Tolerance may be local, meaning that only the specific 
organ is accepted while other donor-type organs would be rejected, or systemic, meaning 
that all donor-type organs would be accepted (1). In our laboratory, the tolerance we seek 
encompasses 1) long-term acceptance of the donor graft with stable graft function 
without continuing immunosuppression, 2) in vitro evidence of donor-specific 
hyporesponsiveness, and 3) an otherwise competent immune system that remains capable 
of responding to third-party antigens. 
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There are four major reasons why scientists aim to reach tolerance in the clinical setting. 
The first, as mentioned above, is that immunosuppressant’s have several drawbacks, 
including potentially severe toxicity as well as a relatively high treatment failure rate, 
meaning that organs are sometimes rejected despite treatment. Even when acute rejection 
episodes resolve, repeated episodes may eventually cause chronic allograft failure. 
 
The second reason is the continuing problem of chronic rejection. As improved induction 
regimens have prolonged graft survival by preventing acute rejection, thereby achieving 
long-term acceptance, it has become increasingly clear that chronic rejection remains as a 
challenge to long-term graft survival. Chronic rejection is poorly understood but is 
thought to result from several factors, which include non-immunologic vascular 
inflammatory processes, innate immunity, and antibody-mediated damage to fibrointimal 
layers of graft vasculature (2). It has been shown to be responsible for late rejection of 
grafts that have avoided acute rejection in both animal models (3, 4) and in the clinic (5-
7). Because of the immunologic component, chronic rejection is less likely to occur if 
tolerance has been induced. 
 
The third reason is the growing demand for organs in comparison to the relative shortage 
in supply. By avoid rejection, tolerance will decrease the need for replacement organs, 
which would be especially difficult to find for these highly sensitized patients (8). 
Tolerance would also overcome the especially large immunologic hurdles that currently 
prevent alternative sources of organs, such as xenotransplantation. 
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Fourth, the induction of systemic tolerance would allow genetically identical organs to be 
interchanged. This has obvious implications for the future if organ cloning, tissue 
engineering, or xenotransplantation from an inbred herd become clinically applicable. 
Regarding the latter, as the thymus is a major component of some current experimental 
xenotransplantation regimens (9) and the juvenile thymus is more effective for tolerance 
induction (10), this would allow a thymus to be taken from a juvenile donor and an 
identical organ from a more size-appropriate donor. 
 
For these reasons, achieving tolerance and understanding its underlying mechanisms has 
long been a goal of transplantation immunology, and it is the driving force behind this 
project. 
 
The Animal Model 
Studies in mice and rats have been responsible for much of the progress which has been 
made in the past few decades in understanding the biology and immunology of 
transplantation.  Unfortunately, however, despite numerous demonstrations of transplan-
tation tolerance in rodent models, there have been few examples in which comparable 
protocols for the induction of tolerance have been successful in large animal models or in 
patients. In fact, most protocols that are successful in rodents, such as those involving 
mixed chimerism, have yet to achieve reliable success in large animal models (11). There 
are also notable differences between rodent and large animal immune systems such as the 
inability to fully deplete T cells in large animals (11) and the lack of constitutive 
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expression of major histocompatibility complex (MHC) class II on the vascular 
endothelium of rodents (12). The lack of antigen presentation by donor endothelium 
obviously affects the immunogenicity of rodent grafts in a way that does not occur in 
large animal models. 
 
It is therefore clear that large animal models are desirable for determining the potential 
clinical applicability of tolerance-inducing protocols.  Miniature swine currently provide 
the only large animal model available in which selective matching for class I and/or class 
II antigens can be reproducibly performed and are therefore of particular significance for 
examining the role of these antigens in tolerance induction as well as in understanding the 
mechanism of the tolerance induced. Inbred miniature swine provide a unique 
opportunity to study transplantation immunity in genetically defined large animals, and 
our herd of partially inbred Massachusetts General Hospital (MGH) miniature swine, in 
which swine leukocyte antigens (SLA) have been well defined, has been utilized 
extensively as a preclinical model for tolerance induction (note: SLA is the swine 
equivalent of human leukocyte antigen (HLA)) (13, 14). It is hoped that studying the 
tolerance observed in this system may reveal new approaches for the induction of 
tolerance in clinical situations. 
 
MGH Miniature Swine 
Miniature swine have been developed over the past thirty-five years as a model system 
for studies of transplantation biology.  Swine were chosen for this purpose because they 
represent one of the few large animal species in which breeding characteristics make 
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genetic experiments possible (13, 15).  At present, there are three homozygous SLA 
haplotypes: SLA
a
, SLA
c
, and SLA
d
. There are also five lines bearing intra-SLA 
recombinant haplotypes as illustrated in Figure 1.  All of these lines differ by minor 
histocompatibility loci, thus providing a model in which most of the transplantation 
combinations relevant to human transplantation can be mimicked.  For example, 
transplants within an MHC homozygous herd simulate transplants between HLA 
identical siblings, while transplants between herds resemble cadaveric or non-matched 
sibling transplants. Likewise, transplants between pairs of heterozygotes can be chosen to 
resemble parent into offspring or one-haplotype mismatched sibling transplants. In 
addition, one subline of SLA
dd
 animals has been chosen for further inbreeding in order to 
produce a fully inbred line of miniature swine (coefficient of inbreeding >94%). These 
animals demonstrate long-term acceptance of all reciprocal skin and organ grafts without 
immunosuppression (14).   
 
Another advantage of these swine is that, for several reasons, they may be the most 
suitable donors of xenografts for humans, largely because of their availability, but also 
because of their favorable breeding characteristics and the similarity of many of their 
organ systems to those of humans. These animals have a variety of properties that make 
them highly suitable as potential donors of xenogeneic tissues and organs:  a) Size:  
These animals achieve adult weights of approximately 120 - 140 kilograms, similar to 
humans;  b) Physiology:  Many organ systems of swine have been shown to be highly 
similar physiologically to their human counterparts, including the skin, the cardiovascular 
system, renal function, pulmonary function, and the digestive system (16);  c) Breeding 
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Characteristics:  Like their domestic counterparts, miniature swine have very favorable 
breeding characteristics for the production of donor animals.  In fact, swine are one of the 
few large animal species in which it is possible to carry out a genetic breeding program.  
Swine have large litter sizes (5 - 10 offspring), early sexual maturity (5 months), short 
gestation time (114 days), and frequent estrus cycles (every three weeks);  d) Potential for 
Genetic Engineering:  Because of these breeding characteristics, it is possible to 
incorporate any number of transgenes into a line of miniature swine designed to be 
appropriate as a donor species.  The most important application of genetic engineering to 
pig donors has been the knockout of Gal expression through nuclear transfer (17-19), 
which has produced the “GalT-KO” animals (see below). 
 
Tolerance of Renal Allografts and the “Basic Model” 
By performing transplants between animals with known haplotypes using the MGH 
miniature swine herd, it has been possible to create models of tolerance induction and to 
gain understanding of the mechanisms behind this tolerance. Initial experiments explored 
the outcomes of transplantation between animals that were either matched for both MHC 
class I and II or were MHC-identical except for either class I or class II. 
 
The Role of “Minor” Antigens 
When renal transplants were carried out without exogenous immunosuppression between 
fully MHC-matched animals, recipients developed specific and long-term (>100 days) 
transplantation tolerance to these grafts in approximately 1/3 of cases (n=112) (20, 21). 
Further study showed that, as these animals were fixed and matched for both MHC loci, 
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rejection was due to non-MHC antigens, otherwise known as “minor antigens” (22). By 
selectively breeding acceptor animals for several generations, resulting generations have 
become more closely matched at minor antigen loci, with the result that spontaneous 
acceptance of fully MHC-matched organs has increased from 27.3% to 64.5% (23). This 
rate of rejection in 1/3 of cases is not only instructive as to the immunogeneic effect of 
minor antigens, even in otherwise identical animals, but it also affects the project 
discussed in this thesis since an important step in our model involves transplantation of a 
recipient-matched kidney without immunosuppression. 
 
The role of minor antigen in the rejection of fully MHC-matched organs is further 
instructive in comparison to its effect in other circumstances. As will be described in 
detail below, we have developed a protocol by which tolerance can be reliably induced to 
renal grafts mismatched for MHC class I. As will also be described in detail below, in 
animals that have become tolerant to these class I mismatched grafts, the original graft 
can be removed and replaced by an organ with the same MHC genotype with a 0% 
rejection rate despite the total lack of immunosuppression. As these replacement organs 
differ from the original grafts in their minor antigens but are never rejected, an interesting 
question, therefore, is why minor antigen differences are responsible for rejection of up to 
1/3 of fully MHC-matched organs (in which there is natural self-tolerance to the MHC 
antigens) but never of MHC-mismatched organs in the scenario above (in which there is 
induced tolerance to the MHC class I antigen). The explanation for this finding illustrates 
the different mechanisms responsible for self-tolerance versus induced tolerance. In brief, 
T cells with specificity for self-MHC do not exist due to negative selection in the thymus 
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(central deletional tolerance), whereas tolerance of MHC-disparate donors involves 
peripheral mechanisms as well, especially via the development of donor-specific 
regulatory T cells (Tregs). It has been shown in both rodent and large animal models that 
in animals made tolerant to a particular antigen, Tregs are able to suppress a response
 
to a 
third-party antigen coexpressed with the tolerated antigen (24-27), a process known as 
“linked suppression.” Similarly, in the presence of Tregs specific for donor MHC, as 
occurs in our model of induced tolerance to donor MHC class I, the coexpression of 
minor antigens would not cause rejection. The mechanisms involved in central and 
peripheral tolerance and the specific role of Tregs in peripheral tolerance will be further 
discussed below. 
 
Transplantation Across a Class I Mismatch 
When renal grafts differed only for one haplotype at class I (e.g., transplantation of SLA
ag
 
organs into SLA
ad
 recipients) and were matched for class II, the rate of long-term 
acceptance after transplantation without immunosuppression in 128 animals was 30%, 
the same as for fully-matched grafts (20, 23). Moreover, those that did accept their 
kidneys did so after experiencing a severe rejection crisis between postoperative weeks 2-
4, with the development of cytotoxic immunoglobulin (Ig) M, but not IgG, directed 
against donor class I. Despite this reaction, the kidneys were accepted with long-term 
normal renal function, and subsequent donor-matched skin grafts survived for an 
extended period of time compared to either third-party grafts or donor-matched grafts 
placed on naïve animals (20). This could indicate that an active immunologic process is 
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responsible for tolerance in this model, and that this process does not produce sufficient T 
cell help to cause rejection. 
 
The development of tolerance following an immunologic reaction involving deficient T 
cell help led to trials in which T cell help was pharmacologically limited via calcineurin 
inhibitors after transplantation. When kidneys were transplanted without 
immunosuppression across a two-haplotype class I mismatch barrier, in which class II 
was identical, they were uniformly rejected within 3 weeks. In contrast, juvenile 
miniature swine (aged 3 to 8 months) that received a short course (12 days) of 
Cyclosporine A (CyA) uniformly experienced long-term tolerance (LTT) specific to the 
donor (n=8) (28, 29), and this result has subsequently been repeated in hundreds of 
animals without rejection. This is referred to as our “Basic Model.” Cyclosporine must be 
given at a high dose (target range 400-800 ng/dl) which, while high enough to have 
toxicity in animals and humans, is tolerable with reversible effects if given in a short 
course (30, 31). 
 
Transplantation Across a Class II Mismatch 
As opposed to class I mismatched grafts, all class II mismatched grafts were rejected 
without immunosuppression (20). However, 5 of 7 animals achieved LTT to these grafts  
after receiving a short course of high-dose CyA (32). 
 
Transplantation Across a Full MHC Mismatch 
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As with class II mismatched grafts, all fully MHC-mismatched renal grafts were rejected 
without immunosuppression. A short course of high-dose CyA prolonged survival but did 
not lead to LTT (28), although it was subsequently found that all animals could be made 
LTT by a short course (12 days) of high-dose (35-80 ng/ml) tacrolimus (FK506) (33). 
 
Potential Mechanisms of Transplantation Tolerance 
Mechanisms of transplantation tolerance have been broadly categorized as “central” or 
“peripheral” on the basis of whether donor-specific T cells are rendered unresponsive or 
deleted during their maturation in the thymus or after they have left the thymus, 
respectively. 
 
Central Tolerance 
As mentioned above, central tolerance is the process via which the bulk of self-tolerance 
is maintained and involves deletion of self-reactive T cells through negative selection in 
the thymus (34, 35), although recent studies show that deletional tolerance of self-
antigens not encountered in the thymus may be mediated by AIRE-expressing cells in the 
periphery (36). Induced central tolerance of non-self antigens similarly occurs through 
deletional mechanisms and has been achieved through mixed hematopoietic chimerism, 
whether following bone marrow transplantation or peripheral administration of 
hematopoietic stem cells (HSC) (37-47). Deletion of alloreactive T cells occurs when 
developing T cells are exposed to alloantigen on HSC, which can occur without 
precondition in utero or during the neonatal period (48) or after ablation of preexisting 
mature T cells later in life (49, 50). 
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Peripheral Tolerance 
Peripheral tolerance takes several forms. The common theme linking all of these forms of 
peripheral tolerance is exposure of alloreactive T cells to antigen in an environment that 
is not conducive towards stimulating an immune reaction such as occurs when 
costimulation, survival signals, or inflammatory cytokines are lacking or if T cell 
activation is actively inhibited by exogenous immunosuppression. 
 
The first form of peripheral tolerance is anergy, which is a state in which T cells 
encounter and recognize their cognate antigen but do not activate or proliferate in 
response to it. It is thought that anergy results when antigen is presented in the absence of 
either costimulation or activating cytokines such as IL-2, and anergy can often be 
reversed by the addition of IL-2 (51, 52). 
 
A second mechanism is peripheral deletion. T cell clones may be deleted either actively, 
by restimulation of activated T cells by large amounts of antigen in the presence of Fas 
and IL-2, or passively, by lack of growth factors or other survival signals, often when 
costimulation is absent (53). One specific form of peripheral deletion is exhaustion. 
Unlike anergy, in which T cells become reversibly unresponsive, exhaustion is an 
irreversible process that can result from a particularly robust immunologic response to an 
antigen. This is thought to cause multiple rounds of replication and continuous 
differentiation of T cells into short-lived cytotoxic effector T cells, which depletes that 
particular clone since it is known that eukaryotic cells only divide a limited number of 
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times. In terms of function, peripheral deletion, including exhaustion, may play an 
important role in eliminating autoreactive T cells (54). 
 
A third mechanism is clonal ignorance, in which T cells fail to encounter their antigen, as 
when antigen resides in immune privileged sites, and fail to activate or provide T cell 
help to effector B and T cells (55). It may also occur if T cells encounter antigen 
presented by non-professional APCs, in which case they sometimes fail to activate (52). 
 
The last peripheral mechanism, and the one on which this thesis focuses primarily, is 
regulation/suppression, in which a population of T cells actively inhibits a specific 
immune response (56, 57). This function results from the action of Tregs, which have 
been identified functionally as suppressors in vitro (58). They have also been identified 
phenotypically by cell surface markers such as CD25, which is often present on Tregs 
(59); by associations with certain cytokines, such as TGF-beta, IL-4, and potentially other 
TH2 signals (60, 61); and by the presence of foxp3 transcripts (62). 
 
Such suppressor cells have been used to explain tolerance in various models. The 
presence of peripheral donor-specific Tregs explains the concept of linked suppression 
discussed above and observed in several animal models (25-27). More broadly, Tregs 
also make possible “dominant tolerance,” which is a state of tolerance that persists once 
attained and includes both linked suppression as well as “infectious tolerance.” Infectious 
tolerance denotes the ability of Tregs from a tolerant animal to render adoptively 
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transferred lymphocytes tolerant or to make a recipient tolerant when adoptively 
transferred themselves in high enough number (27, 63, 64). 
 
Similarly, many of the features of tolerance in the MGH miniature swine model can best 
be explained on the basis of regulatory T cell populations. For example, it has been 
shown that T cells from animals made tolerant to a class I mismatch kidney with a short 
course of high-dose CyA are capable of suppressing anti-donor responses of T cells from 
naïve swine in vitro (65, 66), especially when enriched for CD25+ cells (67). As in rodent 
models, Tregs in the MGH miniature swine model are also capable of linked suppression 
(24). Moreover, preliminary experiments in our laboratory show that adoptive transfer of 
long-term tolerated renal grafts is possible in this model, likely because of donor-specific 
Tregs within the graft (unpublished data). As the presence of a young, active, and 
normally-functioning thymus is required in the recipient for the induction of tolerance in 
this model (10, 68), the mechanism for tolerance most likely involves generation of 
donor-specific Tregs in the thymus. Immediately after transplantation, donor antigen 
reaches the thymus, either by donor APCs (direct antigen presentation) or by recipient 
APCs presenting peptides of donor antigen (indirect antigen presentation). At the same 
time, mature alloreactive T cells are suppressed by the CyA regimen. Therefore, donor 
antigen does not cause acute rejection but has the chance to be presented to newly 
developing T cells, including Tregs that are generated constitutively in the thymus (69). 
These Tregs can then migrate from the thymus and promote peripheral tolerance of the 
donor (70, 71). Of note, there is probably also a small central deletional component that 
contributes to tolerance in this mechanism. 
 18 
 
Recent Breakthroughs in Tolerance 
Two recent findings make tolerance more clinically possible in the near future. In the first, 
new regimens for pig-to-baboon xenotransplants appear to show evidence for T cell 
tolerance. These experiments utilize “GalT-KO” swine, which are pigs that lack the α-
1,3-Galactose (Gal) moiety found on the cell membrane of all species except humans and 
Old World primates and which is the antigen responsible for hyperacute rejection of these 
organs. Baboon recipients of combined kidney/thymus grafts from GalT-KO swine show 
donor-specific unresponsiveness in vitro and early baboon thymopoiesis in the porcine 
thymus tissue (72). The second finding, which has been successfully and reproducibly 
performed in humans, is a new combined bone marrow/kidney transplant regimen that 
has allowed the complete withdrawal of immunosuppression with stable graft function 
(73). 
 
Breaking Tolerance 
Having achieved a method of reliable induction of tolerance across a class I mismatch 
barrier, my laboratory previously explored methods of breaking tolerance with the goal 
that understanding how tolerance is broken will better allow us to understand how 
tolerance can be created and maintained. We have utilized several approaches to breaking 
tolerance, only the last of which has been successful. The first strategy was to perform 
thymectomy on tolerant animals. We found that the induction of tolerance could be 
disrupted by thymectomy during the initial period but that thymectomy at a later time 
point could not break tolerance that had already been created (74). We next attempted to 
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expand the anti-donor alloreactive T cell population. Our attempt to do so via exogenous 
administration of IL2 was unsuccessful (75), and placement of donor-matched skin grafts 
increased anti-donor responses in vitro but did not affect graft function (76). We were 
also unable to break tolerance by infusing primed anti-donor peripheral blood 
mononuclear cells (PBMC) from an animal that had rejected a donor-matched organ 
(unpublished data). 
 
We recently achieved the first successful breaking of tolerance in a large animal model 
by removing the donor antigen from the recipient (nephrectomy of a tolerated class I 
mismatched renal graft) for an extended period of time (referred to as the “absence of 
antigen period”). When a second donor-matched kidney was transplanted without 
immunosuppression either immediately after graftectomy or one month later, the new 
grafts were universally accepted, with a transient creatinine increase in the delayed group. 
However, when three animals were retransplanted three months after removal of the first 
graft, one animal rejected the graft by day 55, and the others eventually accepted the 
second grafts suggesting that a 3-month absence of donor antigens represents the border 
line period for the loss of tolerance (Fig. 2A) (77). 
 
In addition, we found that, unlike our previous attempts to expand the anti-donor 
alloreactive T cell population while the graft was present, doing so during the absence of 
antigen period further accelerated the breaking of tolerance. When donor MHC class I 
peptide was injected midway through the absence of antigen period, anti-donor cellular 
responses increased dramatically, anti-donor IgG was formed, and subsequently-
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transplanted donor-matched kidneys were rejected in 3-5 days with evidence of 
accelerated acute humoral and cellular rejection. Interestingly, however, attempting to 
expand the alloreactive population by placing donor-type skin midway through the 
absence of antigen period had no effect on tolerance. Large anti-donor cellular responses 
were formed in these previously unresponsive animals after skin graft rejection, but no 
anti-donor IgG developed (although a single animal developed IgM). Despite this in vitro 
evidence of T cell sensitization, however, none of these recipients showed accelerated 
rejection of a second donor-matched kidney graft. One of three animals had stable renal 
function until day 30 and then experienced delayed rejection, and the other two accepted 
their kidneys long-term with stable renal function after a transient rise in creatinine 
during the initial period (likely representing acute rejection crisis) (Fig. 2B). Of note, 
these clinical courses are similar to those seen in recipients of 3-month delayed second 
kidney grafts not preceded by skin grafts (77). 
 
The findings described above raise interesting questions regarding the contrasting effects 
of donor-type MHC peptide and skin grafts during the absence of antigen period. Having 
reviewed our model of tolerance induction as well as the mechanisms of tolerance 
involved therein, one can understand how answering these questions might further clarify 
the process of tolerance induction and maintenance. Such was the aim of the work 
described in this thesis. 
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II. Statement of Purpose, Hypothesis, and Specific Aims 
 
As our previous data demonstrate that the breaking of tolerance was accelerated by 
inoculation of previously tolerant animals with donor MHC class I peptide during the 
absence of antigen period but not by placement of donor-type skin grafts (even when 
these grafts were rejected), we hypothesized that, while both donor-type peptide and skin 
grafts are immunogeneic, skin grafts play an additional tolerogeneic role. To evaluate this 
hypothesis, we placed donor-type skin and peptide at the same time during the absence of 
antigen period in the present study.  Our specific aims were as follows: 
1) Confirm the ability of donor MHC class I peptide to sensitize during the absence 
of antigen period when placed alone; 
2) Observe whether donor-type skin grafts fail to sensitize when placed at the same 
time as donor MHC class I peptide during the absence of antigen period as they 
do when placed without peptide (i.e., to assess whether skin grafts merely fail to 
sensitize or whether there is a tolerogeneic effect of skin grafts on previously 
tolerant animals that is strong enough to counteract the powerful immunogeneic 
effect of peptide); and 
3) Use in vitro analysis to evaluate the mechanism behind this novel function of skin 
grafts. 
 22 
III. Methods 
 
Animals 
Transplant donors and recipients were selected from our herd of partially inbred 
miniature swine at 4–7 months of age. These swine have been inbred to homozygosity at 
the class I and class II MHC (termed swine leukocyte antigen [SLA] in pigs) loci, as 
described previously (15). At present, three homozygous haplotypes are available for 
study. In addition, a number of intra-MHC recombinant haplotypes (derived from 
spontaneous recombination events) are also available (78). In this study, the recipient 
haplotype was SLA
dd
 (homozygous class I
d
 and homozygous class II
d
), and the donor 
haplotype was SLA
gg
 (homozygous class I
c
 and homozygous class II
d
). Genotyping has 
been controlled by strict pedigree breeding and confirmed by microcytotoxicity testing 
using allospecific antisera. All transplants in this study were performed on swine that 
were MHC class II matched (i.e., MHC class I and minor antigen–disparate). All donor-
recipient pairs were confirmed to be mutually reactive on a preintervention assay of cell-
mediated lympholysis (CML). All animal care and procedures were in compliance with 
the “Principles of Animal Care” formulated by the National Society for Medical Research 
and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of 
Laboratory Animal Resources and published by the National Institutes of Health (revised 
1996). 
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Kidney Transplantation 
The surgical procedures for kidney transplantation and retransplantation have been 
previously described in detail (28, 68). Briefly, a paramedian incision was made in the 
abdomen, the various tissue layers incised, and the bowels retracted to expose the kidney. 
Gerota’s capsule was dissected away. The ureter, renal artery, and renal vein were then 
sequentially ligated and divided, and the kidney removed. The graft kidney was placed 
orthotopically. The renal vein and then artery were then anastomosed to the inferior vena 
cava and aorta respectively using 6-0 Prolene (Ethicon, Somerville, NJ) running sutures. 
The ureter was anastomosed to the bladder using 6-0 Prolene running sutures. Hemostasis 
was achieved and the abdomen closed. 
 
Skin Grafts 
Split-thickness skin grafts (4×3 cm) were harvested from donors with a Zimmer 
dermatome and placed on graft beds on the dorsum of recipients. Donor-matched skin 
was SLA
gg
. Third-party class I mismatched skin was SLA
hh
 (homozygous class I
a
 and 
homozygous class II
d
). Skin grafts were assessed for viability by color, warmth, and 
softness to touch. They were assessed daily by an observer blinded to the source of the 
grafts and were regarded as rejected when they became dark in color, cool, and rough. 
 
Immunosuppression and Rejection Monitoring 
CyA (Sandimmune) was provided by Novartis Pharmaceutical Corp. (Hanover, NJ) and 
administered as an intravenous suspension. CyA was administered daily at a dose of 10 to 
13 mg/kg (adjusted to maintain a blood level of 400–800 ng/ml) for 12 days, starting on 
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the day of the primary renal transplantation. Whole blood trough levels were determined 
by a monoclonal radioimmunoassay. Rejection was monitored primarily clinically by 
serum creatinine levels and was confirmed by histological analysis of biopsy specimens. 
 
Histopathology and Immunohistochemistry 
Renal open-wedge biopsies were performed during periods of renal failure and at 
postmortem. Allograft rejection was scored by standard pathologic criteria according to 
the Cooperative Clinical Trials in Transplantation criteria (79) (see Table 1). 
Immunohistochemical staining for anti-donor immunoglobulin (Ig) M and IgG deposition 
in renal allografts was examined by fluorescence microscopy using frozen sections 
stained with saturating concentrations of fluorescent isothiocyanate-labeled goat anti-
swine IgM or IgG (68). 
 
Table 1: National Institutes of Health- Cooperative Clinical Trials in 
Transplantation Classification of Acute Renal Allograft Rejection 
Type I Mononuclear infiltrate in >5% of cortex, at least 3 tubules with tubulitis in 
10 consecutive high-power fields from the most severely affected areas, 
and at least 2 of the 3 following features: edema, activated lymphocytes, or 
tubular injury. 
Type II Arterial or arteriolar endothelialitis, with or without type-I features. 
Type III Arterial fibrinoid necrosis or transmural inflammation, with or without 
thrombosis, parenchymal necrosis, or hemorrhage. 
Source: Colvin, Kidney Int. 1996 Sep;50(3):1069-82. 
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Allopeptide Immunization 
As previously mentioned, allopeptide immunization was performed to evaluate the effect 
of sensitizing recipients with donor-type class I MHC peptide. Most of the polymorphic 
sites of the two known class I MHC loci in the pig (designated P1 and P14) are contained 
within the hypervariable regions of the [alpha]1 and [alpha]2 domains, as determined by 
comparison of the MHC class I
c
 (donor type) and MHC class I
d
 (recipient type) genetic 
sequences (80). Four MHC class Ic peptides spanning the full length of the hypervariable 
regions of the P1 [alpha]1 helix were synthesized (81) and labeled as PC1-1 (amino acids 
[aa] 3–27), PC1-2 (aa 35–52), PC1-3 (aa 53–73), and PC1-4 (aa 71–90). Three MHC 
class I
c
 peptides spanning the full length of the hypervariable regions of the P14 [alpha]1 
helix were synthesized and labeled as PC14-1 (amino acids [AA] 3–27), PC14-2 (AA 45–
59), and PC14-3 (AA 60–85). Peptide purity was >90%, as verified by high-performance 
liquid chromatography and mass spectrometry. Peptides were provided by the Biological 
Chemistry and Molecular Pharmacology (BCMP) Biopolymers Lab at Harvard Medical 
School. The length of the peptides was chosen to optimize binding to class II molecules. 
Previous studies have shown that recipients rejecting lung grafts (either acutely or 
chronically) spontaneously develop T cell reactivity to these same peptides and that 
preoperative immunization with these synthetic donor-derived peptides causes 
accelerated rejection in comparison to non-immunized controls (82). 
In this study, 500 µg of each peptide in 750 µL of complete Freund's adjuvant (CFA) 
were injected subcutaneously 6 weeks after graftectomy of the original donor kidney. 
Peripheral blood mononuclear cells (PBMC) from the prospective recipients were tested 
 26 
for in vitro proliferative responses against each individual allogeneic peptide three weeks 
later (see below), and immunized pigs were rechallenged with individual peptides to 
evaluate in vivo delayed-type hypersensitivity (DTH) responses two weeks after 
immunization (see below). 
 
Delayed-Type Hypersensitivity (DTH) Responses 
In the immunized group, DTH responses were evaluated 2 weeks after allopeptide 
immunization by injecting 100 µg of each individual PC1 and PC14 peptide in 0.1 mL 
phosphate-buffered saline (PBS) intradermally into separate sites on the neck of the pig. 
PBS (0.1 mL) was used as a negative control, and 100 µg of Mycobacterium tuberculosis 
H37 RA (MTB) was used as a positive control. Induration was measured 48 hr after 
injection by blinded observers using calipers. Positive responses were defined as having a 
diameter of induration greater than 10 mm. Induration between 5 and 10 mm was 
considered to be an intermediate response, and negative responses had less than 5 mm of 
induration. 
 
Media 
Tissue culture media used for CML assays consisted of Roswell Park Memorial Institute 
(RPMI) 1640 (GIBCO Invitrogen) supplemented with 6% fetal calf serum (Sigma, St. 
Louis, MO), 100 U/mL penicillin (GIBCO Invitrogen), 135 µg/mL streptomycin (GIBCO 
Invitrogen), 50 µg/mL gentamicin (GIBCO Invitrogen), 10 mM HEPES (Fisher 
Scientific, Pittsburgh, PA), 2 mM l-glutamine (GIBCO Invitrogen), 1 mM sodium 
pyruvate (BioWhittaker, Walkersville, MD), 0.1mM nonessential amino acids 
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(BioWhittaker), and 5×10-5M [beta]-2 mercaptoethanol (Sigma). The effector phase of 
the CML assay was performed using Basal Medium Eagle (GIBCO Invitrogen) 
supplemented with 6% CPSR-3 (Sigma) and 10 mM HEPES (Fisher Scientific). 
 
Medium for flow cytometry consisted of Hanks' balanced salt solution (HBSS; GIBCO 
Invitrogen, Carlsbad, CA) supplemented by 1g/L Bovine Serum Albumin and 1g/L 
sodium azide. 
 
Isolation of Peripheral Blood Mononuclear Cells (PBMC) 
PBMC were prepared from freshly collected, heparinized whole blood diluted 
approximately 1:2 with Hanks' balanced salt solution (HBSS; GIBCO Invitrogen, 
Carlsbad, CA) as previously described (68). Mononuclear cells were obtained by gradient 
centrifugation using Lymphocyte Separation Medium (Organon, Teknika, Durham, NC), 
washed once with HBSS, and contaminating red cells were lysed with ACK Buffer (B&B 
Research Laboratory, Fiskeville, RI). Cells were then washed with HBSS and 
resuspended in tissue culture medium. All cell suspensions were stored at 4°C until 
utilized in cellular assays. Antigen presenting cell (APC) and T cell preparations were 
isolated from PBMC by nylon wool passage. 
 
Primary Cell-Mediated Lympholysis Assay 
The procedure for primary CML assays has been described elsewhere (28, 65, 68). 
Lymphocyte cultures containing 4×10
6
 responder and 4×10
6
 stimulator PBMC (irradiated 
with 2500 cGy) were incubated for 6 days at 37°C in 7.5% CO2 and 100% humidity. 
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Bulk cultures were harvested, and effectors were tested for cytotoxic activity on 
51
chromium (Amersham, Arlington Heights, IL)- labeled lymphoblast targets. Effector 
cells were incubated for 5.5 hr with target cells at E/T ratios of 100:1, 50:1, 25:1, and 
12.5:1. Three target cells were tested in each assay: MHC-matched PBMC to the 
effectors, donor-matched PBMC, and third-party PBMC. Supernatants were then 
harvested using the Skatron collection system (Skatron, Sterling, VA) and 
51
chromium 
release was determined on a gamma counter (Micromedics, Huntsville, AL). The results 
were expressed as percent specific lysis (PSL), calculated as: PSL=([experimental release 
(cpm)–spontaneous release (cpm)]/[maximum release (cpm)–spontaneous release 
(cpm)])×100%. For assays in this project, self-type cells were SLA
dd
, donor-type cells 
were SLA
gg
, and third party cells were SLA
hh
, which share class IId with the donor and 
recipient but differ with both by having class Ia. 
 
Secondary Co-culture Cell-Mediated Lympholysis Assay 
As previously described (65), lymphocyte cultures from experimental animals containing 
4×10
6
 cells were primed with donor-type 4×10
6
 PBMC (irradiated with 2500 cGy) and 
incubated as a regulator for 6 days at 37°C in 7.5% CO2 and 100% humidity. Then 
regulator cultures were harvested, and 2×10
6
 regulator cells and naïve matched type 
2×10
6
 PBMC (responder) and 4×10
6
 donor-matched stimulator PBMC (irradiated with 
2500 cGy) were incubated for 6 days at 37°C in 7.5% CO2 and 100% humidity. Bulk 
cultures were incubated with and effectors were tested for cytotoxic activity on 
51
chromium (Amersham, Arlington Heights, IL)-labeled lymphoblast targets. Effector 
cells were incubated for 5.5 hr with target cells at E/T ratios of 100:1, 50:1, 25:1, and 
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12.5:1. Three target cells were tested in each assay: PBMC SLA-matched to the effectors, 
donor-matched PBMC, and third-party PBMC. Supernatants were then harvested using 
the Skatron collection system (Skatron, Sterling, VA) and 
51
chromium release was 
determined on a gamma counter (Micromedics, Huntsville, AL). The results were 
expressed as PSL, calculated as above. Once again, for assays in this project, self-type 
cells were SLA
dd
, donor-type cells were SLA
gg
, and third party cells were SLA
hh
, which 
share class IId with the donor and recipient but differ with both by having class Ia. 
 
Mixed Lymphocyte Reaction (MLR) Peptide Proliferation Assay (PPA) 
To evaluate the ability of a recipient to mount a proliferative T-cell response to an 
indirectly presented peptide antigen, a peptide proliferation assay (PPA) using thymidine 
incorporation was performed as previously described (83). In brief, 4×10
5
 recipient-
matched PBMC were cultured with 50 µg/mL of individual allopeptides for 5 days in 
triplicate plates. The culture was then pulsed with [
3
H]thymidine (1 µCi/well) for 5 hr, 
and [
3
H]thymidine incorporation was measured by [beta]-scintillation counting. A 
stimulation index (SI) for each peptide was expressed as experimental counts per minute 
divided by media control counts per minute. Based on historical data from 30 naïve pigs 
tested against each of three allogeneic class I PC14 peptides (81), the average SI of all 30 
naïve responses was 1.2. Adding three standard errors resulted in an SI of 2.2. Therefore, 
SIs greater than 2.3 were deemed to be significant. 
  
Antigen Presenting Cell (APC) Depletion 
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APCs are known to be adherent and can be negative sorted by adhering to plastic or 
nylon wool as previously described (84, 85). PBMC were incubated for 4 h at 37°C in 
75-cm
2
 plastic flask (Falcon #3023, Becton Dickinson Labware, Lincoln Park, NJ) to 
deplete the adherent cells. To further deplete APCs by negatively sorting adherent cells, 
the overlying media was then gently removed to avoid disturbing the cells attached to the 
flask and was run by gravity through a column of sterile nylon wool (Fenwal 
Laboratories, Deerfield, IL). The flasks were gently washed once with 5 ml of media, 
which was also run through the nylon wool and collected.  
 
The adherent cells (APC-rich cells) in both the flask and nylon wool were also collected 
to use for control plates to compare with the APC-depleted plates. Cells were recovered 
from the flasks by twice adding 5 ml of media, scraping the walls, and aspirating. Cells 
were recovered from the wool by rinsing with 4ml media and aspirating remaining fluid. 
Both adherent and nonadherent cell collections were spun at 1800 rotations per minute 
(rpm) for 10 minutes, placed in 1 ml media, and stored at 4°C for up to 24 hours until 
usage. 
 
Bulk and APC-Depleted Mixed Lymphocytes Reaction (MLR) 
MLR cultures, to test for proliferative response to alloantigen, have been described 
previously (86). Briefly, 4 x 10
5
 responders and an equal number of irradiated (25 Gy) 
stimulators were incubated in triplicate in 200 µl of standard MLR medium using flat-
bottom 96-well plates (Costar, Cambridge, MA). Medium consisted of RPMI 1640 
supplemented with 6% fetal pig serum,10 mM HEPES, 1 mM glutamine, 1 mM sodium 
 31 
pyruvate, 0.1 mM nonessential amino acids, 100 U/mL penicillin, 135 µg/mL 
streptomycin, 50 µg/mL gentamicin, and 2×10
-5
 M [beta]-2mercaptoethanol. Cultures 
were incubated for 5 days at 37°C in 4% CO2 and 100% humidity, after which 1 µCi of 
[
3
H]thymidine was added to each well, followed by an additional 5 hour incubation. Cells 
were harvested onto Mash II glass fibers using a TomTek harvester (Perkin Elmer Wallac, 
Waltham, MA). 
3
H incorporation was determined in triplicate samples by liquid 
scintillation. [
3
H]thymidine incorporation was measured as counts per minute (cpm) 
using the Microbeta liquid-scintillation system (Perkin Elmer Wallac, Waltham, MA). A 
stimulation index (SI) for each reaction was expressed as experimental counts per minute 
divided by media control counts per minute. 
 
For MLR cultures measuring only response to indirectly presented antigen, stimulator 
APCs were first depleted as described above, and this cell solution was used in place of 
the bulk stimulator cell solution. As a control, another set of APC-depleted plates were 
set up identically with the addition of a smaller number of APC-enriched (2.5 x 10
4
) cells. 
 
For assays in this project, self-type cells were SLA
dd
, donor-type cells were SLA
gg
, and 
third party cells were SLA
hh
 (which share class IId with the donor and recipient but differ 
with both by having class Ia), SLA
cc
 (which differs from the recipient in both class I and 
II and shares class Ic with the SLA
gg
 donor), and Yukatan (Yuk, which are completely 
outbred pigs differing at all MHC loci). 
 
Enzyme-linked immunosorbent assay (ELISA) 
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As previously described (87), plates were coated with 50 μL of peptides (2 μg/mL) or 
PBS and incubated overnight at 4°C. The plates were washed twice with 200 μL of PBS 
+ 0.1% Tween20 and then blocked by dispensing 200 μL of PBS + 0.05% Tween20 and 
1% BSA with a 1-hour incubation at room temperature. The plates were then washed 
twice and swine serum at 1:80 dilution in PBS + 0.1% Tween20 was added in triplicate. 
Following a 1-hour incubation at room temperature, plates were washed twice more. 
Rabbit anti-pig IgG (1:250) and IgM (1:250) in PBS + 0.05% Tween20 1% BSA was 
added to each well and incubated for 1 hour at room temperature. Following two more 
washes, 50 μL SAv-HRP developing solution (1:1000) was added to each well and 
allowed to incubate for 1 hour at room temperature and in the dark. Another two washes 
were performed, and hydrolysis was measured adding ABTS peroxidase solutions into 
each well. Product absorbances were measured in optical density (OD) using a BioRad 
ELISA plate reader at 405 nm (BioRad, Hercules, CA). 
 
Flow Cytometry 
As previously described (83), the presence of anti-donor class-I IgM and IgG in the 
serum of experimental swine was detected by indirect flow cytometry. Briefly, serum was 
decomplemented by incubation at 56 degrees Celsius for 30 minutes, and 10 microliters 
of each serum was added to 5 x 10
6
 target cells suspended in 100 microliters. After a 30-
60 minute incubation at 4 degrees Celsius and washing twice with media, 15 microliters 
of appropriate secondary antibody mix containing either a 1:50 dilution of FITC-
conjugated goat Fab anti-swine IgM Fc antibodies (Jackson ImmunoResearch, West 
Grove, PA) or 1:50 dilution of FITC-conjugated goat Fab anti-swine IgG Fc antibodies 
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(Jackson ImmunoResearch). After another 30-60 minute incubation followed by 2 
washes, 10 microliters of propidium iodine at 1:23 dilution was added. Fluorescence-
activated cell sorting (FACS) was performed using a Becton Dickinson FACScan 
microfluorometer (Sunnyvale, CA) and analyzed with WinList analysis software (Verity 
Software House, Topsham, ME). 
 
Complement-mediated Cytotoxicity 
Cytotoxic antibodies binding to target cells were detected by complement-mediated 
cytotoxic assays, as previously described (8).  Target cell suspensions were diluted to 
5×10
6
 cells/mL in Medium 199 (Cellgro, Herndon, VA) supplemented with 2% fetal calf 
serum and serially diluted from 1:10 to 1:160. In 96-well U-bottom plates (Costar, 
Cambridge, MA), 45 µL of the appropriate target cell suspension was incubated with 5 
µL of diluted serum or controls for 15 min at 37
o
C, followed by a second incubation with 
25 µL of appropriately diluted rabbit complement. Dead cells were identified by staining 
for 30 minutes with 10 µL of 7-AAD. Data were acquired, and the percentage of dead 
cells was assessed using a Becton Dickinson FACScan (San Jose, CA) and analyzed with 
WinList analysis software (Verity Software House, Topsham, ME). 
 
Contribution of Student Researcher 
Joshua Weiner performed all procedures and analysis detailed in the Methods and Results 
sections. David Sachs and Kazuhiko Yamada advised me in analysis. Yoshinori Ishikawa, 
Kazuhiko Yamada, Justin Etter, and Shannon Moran assisted in surgeries. Justin Etter, 
Shannon Moran, and Hanzhou Hong provided occasional technical support with assays. 
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IV. Results 
 
Immunogenicity of Peptide 
It has been demonstrated previously that inoculation with donor MHC peptide sensitizes 
recipients to reject grafts bearing the same donor MHC in an accelerated fashion (81, 82, 
87, 88). Before conducting our experiment, we first demonstrated that our batch of donor-
type class Ic peptide was also immunogeneic. This was demonstrated in two ways. First 
we inoculated a naïve SLA
dd
 pig (pig #17050) with class Ic peptide and observed in vitro 
and in vivo responses. We found that the animal responded to the peptide in vitro with 
increased MLR responses in a peptide proliferation assay (Fig. 3A) and with production 
of anti-peptide IgG in an ELISA (Fig. 3B), but it did not produce antibody against SLA
gg
 
cells, which display MHC class Ic (Fig. 3C). MLR response to SLA
gg
 cells increased 
dramatically after peptide inoculation, especially when antigen was indirectly presented 
(Fig. 4A).  This is consistent with the idea that the pig was sensitized on an indirect level 
since peptide can only be presented indirectly. Although anti-donor MLR responses were 
increased after peptide, CML responses to donor cells did not increase after peptide 
inoculation (Fig. 4B). When this sensitized pig was then injected with SLA
gg
 PBMC 59 
days after peptide inoculation, both direct and indirect anti-donor responses increased 
even further (Fig. 5A), and both large anti-donor CML responses and SLA
gg
 IgG now 
formed as well as shown in Figures 5B and 6. 
 
Second, we demonstrated that our batch of peptide was capable of sensitizing recipients 
in a manner capable of causing accelerated rejection of a subsequently placed SLA
gg
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kidney (in this case 21 days after peptide inoculation). When this animal (pig #18524) 
was injected with peptide, anti-donor MLR responses formed as before, and the kidney 
was rejected in an accelerated acute cellular and humoral fashion as evidenced by 
increase in anti-donor CML response (data not shown), acute increase in creatinine and 
fall in platelets (Fig. 7A), and the large, hemorrhagic-appearing graft at necropsy (Fig. 
7B). Of note, this result occurred despite our normal CyA induction regiment with which 
100% of class I mismatched kidney grafts are accepted in non-sensitized animals. 
 
Experimental plan 
Having shown that our batch of peptide was immunogeneic, we evaluated the 
combination of peptide-plus-skin during the absence of antigen period. Juvenile SLA
dd
 
swine were made tolerant to two-haplotype class I mismatched/class II matched renal 
grafts from SLA
gg
 swine with a 12-day course of cyclosporine A (CyA) as previously 
described (28). After these animals displayed long term tolerance (approximately 100 
days with stable renal function and in vitro evidence of donor-specific 
hyporesponsiveness), a 3 month “absence of donor antigen” period was created by 
removing the renal allograft for 12 weeks. In order to maintain renal function in the 
recipients while the donor renal grafts were absent, recipients were given a self-type 
(SLA
dd
) kidney on the day of graftectomy. Grafts that are fully MHC-matched but differ 
in minor antigens are typically accepted without immunosuppression in approximately 
2/3 of recipients in our experience, sometimes with a transient and minor increase in 
creatinine approximately 1 week postoperatively. Six weeks after the nephrectomy of the 
primary kidney (i.e., 6 weeks prior to the second donor kidney transplant), recipients 
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were challenged simultaneously with donor-type (SLA
gg
) skin grafts and subcutaneous 
injection of donor MHC class I (class Ic) peptides. After an additional 6 weeks, a second 
donor-type (SLA
gg
) kidney was transplanted without immunosuppression. The 
experimental plan is detailed in Figure 8. 
 
Anti-donor responses in the initial period  
Induction of tolerance of class I disparate renal allografts 
We have previously reported that a 12-day course of CyA facilitated the induction of 
tolerance of class I disparate renal allografts in juvenile (3-8 months of age) MGH 
miniature swine (28). This was the case in all 5 of our experimental animals as well. The 
clinical courses of 3 of these animals were unremarkable with stable creatinine 
throughout. Two animals (18349 and 18354) had early peaks in creatinine that were 
found to be caused by ureteral stenosis during exploratory surgery, and the problem 
resolved with reanastomosis. By the time of graftectomy, all 5 pigs had creatinine stably 
in the normal range and showed donor-specific unresponsiveness or hyporesponsiveness 
on in vitro assays. In the 3 animals for whom these data were available, secondary co-
culture CML showed suppression of naïve recipient-matched cells against donor-type 
cells. 
 
Small increase in anti-donor responses in some swine during absence of antigen period 
We have previously documented that anti-donor cellular responses increase slightly after 
the removal of the donor-kidney and replacement with recipient-matched kidney (the so-
called “absence of antigen period”) (77). We have also shown that roughly 1/3 of the 
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recipient-matched kidneys are rejected due to disparities in minor antigens (20). This 
pattern was seen in our experimental animals. One animal rejected its matched kidney at 
day 35 and was saved by a rescue transplant of another recipient-matched kidney. Biopsy 
at the time of graftectomy showed cellular but not humor rejection, consistent with a 
process mediated by minor antigen differences. The other animals experienced only very 
slight creatinine increases between days 10-12. In 4/5 animals, there was a small increase 
in anti-donor CML responses in the absence of antigen, although no increase in MLR 
response. 
 
Effects on tolerance of combined donor-type skin plus class I peptide during the 
absence of antigen period 
Recipients reacted to peptide in vivo and in vitro 
All 5 experimental animals reacted to the donor-type Class I peptide in vivo and in vitro. 
Delayed type hypersensitivity (DTH) responses to class Ic peptides were analyzed in all 
recipients immunized with the class Ic PC14 peptides 14 days after inoculation. PC14-3 
elicited the strongest positive DTH response in the immunized animals. The immunized 
pigs showed brisk DTH responses to the M. tuberculosis H37 RA positive control and 
negative responses to the phosphate-buffered saline control. These results confirmed the 
presence of indirect alloantigen presentation in vivo and validated the immunogenicity of 
specific class I MHC peptides. To assess the in vitro reactivity of recipient lymphocytes 
to individual class Ic peptides, MLR peptide assays were performed with lymphocytes 
from these animals three weeks after immunization in the absence of donor kidney 
antigens. There was no T cell proliferative response to any of the PC14 (class Ic) peptides 
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before immunization. After immunization, T cell responses to PC14-3 developed, which 
was consistent with the positive DTH responses observed 14 days after immunization. 
3/5 swine also had increases in IgG directed against the peptide on ELISA. 
 
Skin survived same length of time as when placed without peptide 
Donor-matched (SLA
gg
) skin grafts all engrafted initially and were then rejected between 
15-18 days later. Of note, this is the same length of survival as when skin was placed 
without the concurrent inoculation with peptide in tolerant animals during the absence of 
antigen period (77). We also found that skin grafts briefly became darker and more 
mottled between 6-9 days after placement. This could represent vascularization, but it 
could also be a rejection crisis during which the alloreactive and tolerogeneic reactions 
compete and thereby, presumably, provide the immunologic stimulus for the 
development of Tregs. Therefore, to evaluate this hypothesis, we set up a primary co-
culture in 2 animals 7 days after skin grafting. If this was a time of Treg stimulation 
expansion in the blood, it might be possible to see suppression of naïve anti-donor 
response by these cells. However, we instead saw an increase in the anti-donor response 
(data not shown). Possible reasons for this finding are outlined in the Discussion. 
 
Anti-donor cellular responses increased after skin-plus-peptide 
All animals had increased specific CML responses to donor cells after skin-plus-peptide. 
These responses were large in 3 animals and moderate in 2, and the differences did not 
correlate with whether these animals eventually rejected their kidneys (Fig. 9). All 
animals also had increased specific MLR responses to donor cells. In two animals, this 
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response was seen only in the bulk wells but not in the wells in which indirect antigen 
presentation was isolated. In 2 animals, the responses were higher in the indirect wells 
than in the bulk wells. The absence of indirect response did not correlate with whether 
these animals eventually rejected their kidneys, however the predominance of the indirect 
response was seen in the 2 animals who survived longest after their second donor-
matched kidney transplant (Fig. 10). 
 
Possible increase in suppressive cells 
Flow cytometry showed no consistent changes in Foxp3 cell number or percentage in 
peripheral blood after skin-plus-peptide; however, 3 of 4 animals tested had increased 
CD25+ and CD25/CD4++ cell percentages during this period (data not shown). This 
might potentially represent an expansion of cells capable of performing a regulatory 
function during the period after skin-plus-peptide. 
 
Clinical course after transplantation of 2
nd
 donor-matched kidney (SLA
gg
) without 
immunosuppression 
In our previous experience, differences in survival were stark after 2
nd
 donor-matched 
kidney transplantation without immunosuppression when either donor-type skin or 
peptide were placed solitarily during the absence of antigen period. Swine that received 
peptide alone rejected their kidneys in an accelerated acute humoral and cellular fashion 
within 3-5 days; those that received skin alone either survived long-term or rejected in a 
delayed fashion (77). Our purpose in this current experiment was to evaluate which of 
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these effects would predominate when animals were challenged simultaneously with skin 
and peptide. 
 
Upon reperfusion of the 2
nd
 donor-matched kidneys, we observed spot hemorrhages in all 
grafts within 1 hour. This is consistent with the deposition of preformed anti-donor 
antibody which developed during the absence of antigen period, most likely after skin-
plus-peptide. Two of these animals developed slightly larger areas of darkness in their 
grafts but continued to make urine soon after reperfusion. Another 2 animals, despite 
patent anastomoses and adequate renal artery pulse, developed diffusely dark kidneys 
which felt soft to the touch and produced very little urine during surgery. 
 
We found that 2 of 5 animals survived long-term after receiving a second donor-matched 
kidney without immunosuppression. An additional animal experienced slightly prolonged 
survival (11 days). The final 2 animals rejected within 5-7 days with acute increases in 
creatinine and eventually uremia and internal bleeding. Figure 11 shows survival of all 
five animals after second donor-matched kidney transplantation compared to pigs who 
received either peptide or skin alone. Figure 12 shows creatinine levels for the five skin-
plus-peptide animals after their second donor-matched kidneys. Of the long-term 
survivors, one (17944) experienced a mild and transient rise in creatinine between 
postoperative days 8-10. Creatinine then returned to baseline and remained at that level 
throughout. Note that the slight increase in creatinine at the end of this animal’s course 
was due to severe pneumonia diagnosed clinically and confirmed by necropsy and 
histology. The other long-term survivor (18354) experienced a more pronounced early 
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rise in creatinine, which eventually returned to baseline. The large increase in creatinine 
in the later part of this animal’s course was due to a prolonged period of sepsis, which 
required treatment with intravenous fluids and multiple rounds of antibiotics. 
 
The correlation between appearance of the kidney during surgery and survival was not 
perfect. However, the two longest surviving kidneys showed either mild spot 
hemorrhages or slightly larger darker areas with urine production. The other kidney with 
larger areas of darkness and urine production was in the animal that experienced slightly 
prolonged survival. The kidneys that were diffusely dark and soft without urine 
production were in the two animals with the shortest survival. 
 
In all second donor-matched kidneys, histology showed IgM and IgG deposition as early 
as 1 hour after reperfusion, which is consistent with our intraoperative observations. 
Additional findings are as follows. In the first long-term surviving animal, histology after 
sacrifice showed grade II cellular rejection. The second long-term survivor showed no 
evidence of rejection of necropsy but had slight glomerulitis of uncertain etiology. The 
animal who rejected on day 7 showed acute humoral rejection at necropsy. At time of 
submission, final analysis of histology data from necropsy of the other two early rejectors 
was still being completed, but we believe that the results will also show acute humoral 
rejection based on the gross appearance of these organs at necropsy. Figure 13 contrasts 
the gross necropsy findings in long-term acceptors versus rejecters.  
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In vitro responses after 2
nd
 donor-matched kidney (SLA
gg
) without immunosuppression 
In vitro responses correlated with clinical course after second donor-matched kidney 
transplantation without immunosuppression. In the two animals that survived long-term, 
CML responses against donor cells, which had increased after skin-plus-peptide, became 
negligible within the first month after transplantation. The animals maintained normal 
CML responses to 3
rd
 party cells (Fig. 9). 
 
Bulk and indirect MLR responses could not be assessed in animals who rejected in the 
early period after transplantation. However, in the two animals who survived long-term 
with stable renal function, both bulk and indirect MLR responses, which had increased 
after skin-plus-peptide, became negligible after transplantation. Third-party responses 
remained appropriate (Fig. 10). 
 
Neither clinical course nor in vitro responses were affected by additional donor-antigen 
challenge after transplantation 
The two animals who maintained their second donor-matched grafts long-term were 
further challenged with additional donor antigen. In one animal, challenge was in the 
form of a second donor-matched skin graft, which was placed 2 months after the renal 
graft. Self and third-party grafts were placed at the same time. The donor skin was 
rejected after 17 days, which is the same kinetics as when donor skin is placed either in 
an animal bearing a tolerated kidney graft or during the absence of antigen period after 
this graft has been removed. In contrast, a self skin graft was accepted indefinitely, and a 
third-party skin graft was rejected within 5 days. The other long-term surviving animal 
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was challenged by an additional inoculation with donor-type Class Ic peptide 2 months 
after the renal graft. In both pigs, renal function was entirely unaffected, and there was 
either a small or negligible increase in anti-donor CML and MLR responses. In the 
animal who was challenged with skin, both MLR and CML responses to the third party 
donor increased, and anti-third-party IgG became detectable in the serum within 1 week. 
No anti-donor antibodies were detectable. 
 
The role of humoral responses 
The contribution of humoral responses in this experiment was complex. It is now the 
focus of our ongoing research and will be addressed in detail in the future. Briefly, 
however, levels of anti-donor IgG peaked roughly 2 weeks after skin-plus-peptide and 
thereafter decreased in the animals who had long-term or prolonged survival . These 
antibodies were found to be only minimally cytotoxic against donor cells in our 
complement-dependent antibody-mediated cytotoxicity assays. In contrast, levels of anti-
donor antibodies were consistently significantly elevated and highly cytotoxic in the two 
animals who rejected most quickly (data not shown). 
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V. Discussion 
 
In the absence of exogenous immunosuppression, skin grafts are usually quite 
immunogenic, and the sensitization caused by these grafts causes accelerated rejection of 
a donor-matched graft placed later. However, we have previously shown that, when 
placed on tolerant swine in whom the original donor organ has been removed for several 
weeks, donor-matched skin grafts do not appear to have this effect. When a new donor-
matched kidney is placed without immunosuppression 6 weeks after skin, rejection is not 
accelerated, and the new organs may even survive indefinitely. This is similar to the 
pattern seen when no skin graft is placed during the absence of antigen period but stands 
in stark contrast to the accelerated rejection that occurs when donor peptide is placed 
during this time (77). 
 
By challenging recipients with both donor-type peptide and skin at the same time during 
the absence of antigen period, we now demonstrate not only that donor skin does not 
hasten its own rejection but that the concurrent inoculation with donor skin and peptide 
also does not hasten rejection of donor skin and at least partially negates the 
immunogeneic effect of peptide alone. When recipients are inoculated with peptide alone 
during the absence of antigen period, tolerance is always broken, and future grafts are 
rejected by severe acute cellular and humoral rejection within 3-5 days (77). When skin 
and peptide were placed together, however, tolerance was preserved in 2 of 5 animals, 
and survival was prolonged in a third. In the 2 long-term survivors, kidney function 
remained normal after the initial period. Moreover, in vitro parameters of tolerance were 
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restored. Both anti-donor MLR and CML responses, which had increased substantially 
after skin-plus-peptide, once again became hyporesponsive or unresponsive. Finally, this 
tolerance was found to be stable and could not be broken even by additional inoculation 
with donor-type skin or peptide, neither of which affected function of the donor kidney or 
increased anti-donor responses in vitro. 
 
Although the number of animals in this series was not large, the difference between the 
accelerated acute rejection seen in all animals receiving peptide alone versus the 
possibility of long-term survival in the skin-plus-peptide group was dramatic, and we saw 
a difference in in vitro parameters between the groups as well. 
 
The most likely mechanism for this phenomenon involves the balance between 
alloreactive and suppressive T cells. The evidence for this lies in several observations 
from our well-established model, in which we reliably induce tolerance of Class I 
mismatched renal allografts, and in other models of tolerance induction. We have shown 
that tolerant animals have stable graft function and in vitro evidence of donor-specific 
hyporesponsiveness (28). Moreover, T cells from these tolerant animals are capable of 
suppressing the anti-donor responses of naïve T cells when cultured together, which is 
compatible with the idea that Tregs develop after transplantation and play an integral role 
in maintaining tolerance peripherally (65, 67, 89). 
 
Because of these Tregs, tolerance cannot be broken as long as the graft remains in place, 
even if the recipient is challenged with either donor skin or peptide. Graft function 
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remains normal even if CML responses are increased (76, 90-92). Even though 
tolerogeneic or suppressive host cells infiltrating the graft may help maintain tolerance at 
the local level (93), the maintenance of tolerance in our model is more a function of the 
host than of the graft as we and others have shown that tolerance is maintained if the graft 
is removed and immediately replaced with a donor-matched organ without 
immunosuppression. In fact, we have shown that tolerance is maintained for up to 4 
months in the absence of antigen (77), and this time period is even longer in the rodent 
model (94). Beyond this time period, however, rejection of donor-matched organs begins 
to be observed (63). 
 
The most likely mechanism for these observations is the changing balance between Tregs 
and alloreactive T cells over time. Tregs progressively decrease in number, potency, 
and/or affinity after donor tissue has been removed (91, 94, 95). On the other hand, 
unlike in central (e.g., deletional) mechanisms of tolerance, alloreactive cells remain 
present in our tolerant animals, as indicated by the increased anti-donor CML responses 
when donor-type class I/third-party class II skin grafts are placed during this time (data 
not shown). Therefore, the relative balance between the residual Tregs and alloreactive 
memory cells at any given time determines whether grafts are rejected or whether 
tolerance is preserved, and the progressive decrease in Tregs is the most likely reason 
why tolerance is lost with time (77, 92, 94, 96). Evidence for this can be seen in our 
demonstration that anti-donor CML responses increase during the absence of antigen 
period.  
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As outcomes differ dramatically when recipients are challenged with peptide versus skin 
during the absence of antigen period, we propose that the particular balance of Tregs and 
alloreactive cells differs between these two processes. There are several possible 
mechanisms that could explain this difference. One involves the type of antigen presented. 
As the injected peptide is simply a polypeptide portion of the MHC class Ic antigen, only 
class I antigen can be presented after peptide inoculation. However, a wide range of 
donor antigens can be presented after skin grafting, including both MHC antigen as well 
as minor antigens. Presentation of these other donor antigens may expand the Treg 
population in a way not possible with presentation of Class I peptide alone. It is known 
that presentation of MHC peptides is much more immunogeneic than presentation of non-
MHC peptides (97), and it is therefore possible for presentation of non-MHC peptides to 
lead to a tolerogeneic state (98-101). 
 
A second possible mechanism involves the manner in which host APCs present donor 
tissue antigens versus peptide. That is, tissue antigen may be taken up by APCs and 
presented in draining lymph nodes in a way that favors lack of alloreactivity relative to 
suppression or anergy. The predominance of dendritic cells may somehow play a role in 
this mechanism. In contrast, presentation of peptide antigen may occur more diffusely by 
various APCs throughout the body and in a way that favors expansion of alloreactive 
cells relative to Tregs. 
 
A third reason is that placing donor-matched skin during the absence of antigen period  
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simply affects the kinetics of Treg loss since it literally restores the presence of antigen. 
We and others have demonstrated that, once tolerance has been created, it is not possible 
to break as long as the graft remains in place (63, 76, 102, 103). 
 
A fourth and less likely hypothesis is that any remaining DCs in the graft may be in an 
immature form that does not express much MHC Class II, CD80, or CD86. It has recently 
been shown that immature DCs, such as those found in cornea grafts after transplantation, 
may cause T cells to become Tregs rather than alloreactive cells (104). However, it might 
be that these immature DCs exist only in immunoprivileged sites and are not found in our 
model. Nonetheless, the idea of tolerance facilitated by antigen presentation by immature 
or semi-mature DCs has been proposed elsewhere as well (105-107). 
 
While any of these hypotheses could explain our findings, we propose that the most 
likely mechanism involves the particular mode of allopresentation (i.e., direct versus 
indirect presentation). As peptide immunization lacks actual donor cells, including APCs, 
the donor antigen can be presented only indirectly; in contrast, antigen can be presented 
both directly and indirectly after skin grafting as the grafts include donor APCs. 
 
There are two ways in which direct allopresentation may contribute to a tolerogeneic 
state. The first is that only in direct allopresentation is cell-to-cell contact possible 
between donor APCs and recipients CD4+ T cells. We have previously shown that this 
cell-to-cell contact is necessary for the expansion of the Treg population (65). Therefore, 
direct presentation in previously tolerant animals would allow for the expansion of the 
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Tregs in a way not afforded by indirect presentation (108). Evidence for this hypothesis 
can be seen in our flow cytometry data showing that, while foxp3+ cells do not increase 
after placement of skin and peptide, CD25+ and CD4+/CD25+ T cells do. It is not clear if 
the lack of increase in foxp3+ cells is significant. Perhaps our assay is not sensitive 
enough for detecting subtle changes in peripheral blood, which has very low numbers of 
foxp3+ cells. It is also possible that we observed an increase in induced Tregs as opposed 
to natural Tregs. 
 
This model supposes that, while Tregs are expanded by direct allopresentation after skin 
grafting, they are not activated by peptide since cell-to-cell contact between donor and 
recipient cells is not possible through the indirect pathway alone. On the other hand, 
alloreactive cells, which remain present at low levels, are stimulated by peptide through 
the indirect pathway in a way that Tregs cannot be. The activated alloreactive cells, in the 
setting of relatively decreased Treg number or potency in the absence of antigen, would 
then be able to provide T cell help to both cytotoxic T cells and B cells. 
 
The second mechanism by which direct allopresentation may contribute to a tolerogeneic 
state is that direct allopresentation by non-APCs may play a progressively tolerogeneic 
role after transplantation. Direct presentation certainly contributes to rejection in the early 
period when the presence of donor APCs is highest (97). However, direct presentation 
plays a decreasing role in rejection with time, mostly because the number of donor APCs 
decreases with time (81, 109-112). This is also seen in human allograft recipients (113). 
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Not only does direct presentation plays a decreasing role in rejection with time, but it also 
appears to play an increasingly tolerogeneic role as donor APCs decrease, thus leaving 
the remaining direct presentation by non-APCs alone (81, 113). In this hypothesis, donor 
APCs initially migrate to host lymph nodes, where they activate alloreactive T cells. 
These T cells migrate to the graft, where they secrete cytokines that stimulate graft 
endothelial cells to express Class II. In a long-term surviving graft, these Class II-
expressing donor cells are all that remain of direct presentation once donor APCs are 
depleted over time. As they neither express costimulation nor migrate to lymph nodes, 
they foster either anergy or suppression (114-116). Tolerance created through this 
mechanism has been shown to persist even if costimulation is eventually added (117). In 
fact, after the acute period, the presence of donor antigen expressed by Class II on donor 
cells seems to inhibit cell-mediated rejection as grafts lacking Class II expression are 
rejected more rapidly (97). It has been shown that direct presentation by graft endothelial 
cells, which express class II but are not professional APCs, downregulates anti-donor 
activity through interactions with donor-specific primed/memory T cells (CD45RO+). 
These alloreactive memory cells decrease after encountering donor antigen presented 
directly by non-APC donor cells (such as class II-expressing vascular endothelium) while 
CD45RA+ (naïve) cells do not. This is substantiated by fact that CD45RO+ cells 
circulate to the graft, while CD45RA+ cells do not, and that CD45RO+ cells decrease in 
number after contact with alloantigen presented by parenchymal graft cells (117, 118). 
More specifically, these potentially tolerogeneic graft parenchymal cells seem to have a 
tolerogeneic effect on both memory and naïve cells. For memory cells (CD45RO+), the 
mechanism seems to be anergy, since responses are restored by IL-2 in culture. For naïve 
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cells (CD45RA+), the mechanism seems to be deletion subsequent to activation without 
costimulation, as the process can be prevented by blocking the CD95 receptor (117).  
 
Since it seems that direct allopresentation without costimulation is at least partially 
responsible for fostering a tolerogeneic state, the question becomes why?  The most 
likely answer is that it modulates the cytokine profile. It has been demonstrated that such 
“sustained suboptimal antigenic stimulation” fosters peripheral generation of both natural 
and induced Tregs through a pathway requiring the presence of TGF-beta, which both 
raises the threshold for T cell activation and directly promotes differentiation into Tregs 
(119). This is consistent with recent studies showing that TGF-beta plays a large role in 
the formation of Tregs (120, 121). This pathway may also engender tolerance through 
resulting release of IL-4 or IL-10 and activation of the Th2 pathway (119, 122). Although 
controversial, there is some evidence that Th2 pathway, and its cytokines, can help 
facilitate a tolerogeneic state (123). In euthymic hosts, the mechanism appears to be a 
mixture of anergy and suppression, with the suppression seemingly depending on 
cytokines such as IL-10, IL-4, and IL-2, which possibly function to foster an environment 
favoring Th2 T cell activity (63). This could explain one mechanism by which direct 
allopresentation fosters tolerance and could also explain the decrease in suppression as 
these cytokines decrease in the absence of antigen.  
 
As our hypothesis involves a balance between alloreactive and tolerogeneic cells, a 
logical extension is that the effect of skin is not all-or-nothing but rather a spectrum in 
which competition between the alloreactive effects of both peptide and skin and the 
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tolerogeneic effect of skin determines where on the continuum between rejection and 
tolerance the animal will fall. This would explain why anti-donor cellular and humoral 
responses differed between animals. As of yet, we do have not identified a marker that 
predicts which competing impulse will win. 
 
In previous experiments, we have been able to observe the competition between the 
immunogeneic and tolerogeneic impulses in the form of rejection crises within the first 2 
weeks after transplantation followed by long-term tolerance. We believe that this struggle 
represents the initial alloresponse, during which activation and expansion of both 
alloreactive and tolerogeneic cell populations occur. Evidence for this is that Treg 
upregulation requires exposure to antigen and T cell activation (56, 66, 124-127), and we 
have shown that, in the early period after transplantation, the population of recipient T 
cells and macrophages infiltrating both accepting and rejecting grafts were relatively 
similar (128). Moreover, when long-term tolerance occurs after transplantation of one-
haplotype class I mismatched renal grafts without immunosuppression, it is preceded by a 
severe rejection crisis with formation of IgM but not IgG directed against donor class I 
(20, 23). This finding serves as additional evidence that an active immunologic process 
contributes to Treg development. Conversely, it has been shown that suppressing T cell 
activation and IL-2 formation via calcineurin inhibitors during the early period after 
transplantation interferes with expansion and maintenance of Tregs and inhibits long term 
tolerance (129). 
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We similarly observed the competition between immunogeneic and tolerogeneic 
impulses in our current model. For example, it could be seen after the second donor-
matched kidney transplantation in the two animals that survived long-term. In both, 
creatinine increased transiently during the first 2 weeks before returning to baseline. It 
could also possibly be seen in the brief period of darkening and mottling of the donor 
skin grafts roughly 1 week after transplantation, after which the skin returned to a lighter 
shade until ultimately rejected due to skin-specific antigens. Both observations are 
consistent with the hypothesis that the Treg population was expanded by direct 
allopresentation at these timepoints, although at least some component of the change in 
skin color could have resulted from new vascularization. Evidence for the struggle 
between immunogeneic and tolerogeneic impulses could also be seen in our in vitro data 
as both anti-donor CML and MLR responses increased after skin-plus-peptide. While this 
finding certainly represents expansion of the alloreactive T cell population, it could also 
represent the alloresponse necessary for the expansion of the Treg population. 
 
The timing of this immunologic struggle is likely important. It is highly probable that, if 
donor skin were placed in the days or weeks after peptide inoculation rather than 
simultaneously, the unopposed action of the peptide would lead to expansion of the 
alloreactive population without the concurrent tolerogeneic effect. Therefore, we suspect 
that both the donor skin and subsequently the second donor-matched kidney would be 
rejected in an accelerated fashion. 
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To date, we have been unable to prove this hypothesis via in vitro assays. Primary co-
culture assays using peripheral blood drawn when the skin grafts grew darker show 
increased rather than suppressed anti-donor responses. Therefore, we cannot say 
definitively that there is expansion of a Treg population that is capable of suppressing 
naïve or memory alloreactive T cells during this time. It is possible, however, that there is 
expansion of a Treg population during this time that either does not have a suppressive 
effect in vitro or that does not show such an effect until later. Regarding the former, we 
and others have shown that demonstration of neither donor-specific hyporesponsiveness 
nor in vitro suppression is necessary for long-term survival of a graft (90). Moreover, our 
assays may not be sensitive enough to show a suppressive effect from a number of Tregs 
that may be clinically significant but whose effect is so closely balanced with that of an 
alloreactive population as to be undetectable in vitro. Regarding the idea that an in vitro 
suppressive effect might not be apparent until days to weeks later, a secondary CML co-
culture assay performed just prior to second donor-matched kidney transplantation in an 
animal that later accepted its second kidney long-term did not show a suppressed anti-
donor response (data not shown). This could further indicate that a Treg expansion that is 
clinically significant might not be detectable in vitro. It could also mean that our Treg 
expansion hypothesis is incorrect. 
 
Finally, we draw a few limited conclusions regarding humoral immunity. First, we see 
that, while class Ic peptide immunization in naïve swine causes formation of antibody 
directed against peptide but not against SLA
gg
 cells. Anti- SLA
gg
 antibody forms only 
when recipients are exposed to actual donor tissue, whether in the form of PBMC, skin, 
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or kidney. This illustrates an important concept about the conformation of the class Ic 
peptide we inject as compared to actual MHC class Ic. Proteins have a specific 
conformation, which is determined by the chemical properties and sequence of their 
amino acids. Antibodies directed against a portion of the protein recognize both the 
sequence and the conformation. However, if the same portion of the protein is isolated as 
a polypeptide, it may fold in the native conformation (the conformation in which it exists 
in the protein) or in any number of other random conformations (130-132). This is 
depicted artistically in Figure 14. 
 
It remains unclear why class Ic peptide immunization sensitizes recipients against SLA
gg
 
cells on a T cell level without stimulating the production of antibody against SLA
gg
 cells 
as exposure to actual donor tissue does. The reason likely involves differences in 
conformations between the injectable class Ic peptide and MHC class Ic as discussed 
above. Given the lack of anti-donor antibody production after inoculation with class Ic 
peptide in naïve animals, it also remains unclear as to how antibody against SLA
gg
 is 
produced after peptide inoculation during the absence of antigen period. As we have 
shown that anti-donor antibody (as opposed to anti-peptide antibody) forms only after 
exposure to actual donor tissue, and these animals were previously exposed to a donor 
kidney, the most likely scenario is that B cells were primed against donor antigen earlier 
when the kidney graft was present but did not produce antibody until exposed to peptide 
during the absence of antigen period. One possible explanation for this is that the 
continued presence of donor antigen in a tolerant animal has some sort of suppressive 
effect on B cells, much as we propose that it has on T cells (perhaps through the same 
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direct antigen presentation mechanisms hypothesized above). This would be the first time 
that such an effect is demonstrated. These questions are now the focus of ongoing 
research in our laboratory. 
 
The second limited conclusion we draw regarding humoral immunity is that there appears 
to have been some form of anti-donor humoral response following skin-plus-peptide 
challenge, and differences in this response seem to correspond with different outcomes. 
We previously described a strong anti-donor humoral response after inoculation with 
peptide alone during the absence of antigen period, including anti-donor IgG seen on 
flow cytometry and dark kidneys after reperfusion of donor-matched kidney grafts 
followed by low urine output that never increased, death within 3-5 days, and evidence of 
accelerated acute humoral rejection on histology. In our current experiment, we similarly 
demonstrated an antibody response in vivo after skin-plus-peptide as evidenced by the 
presence of spot hemorrhages after reperfusion of the second donor-matched kidney graft, 
the early damage to some of the grafts on physical inspection (dark and soft with little 
urine production), the antibody deposition seen on immunohistochemistry as soon as 1 
hour after reperfusion, and the large and hemorrhagic appearance of grafts that rejected 
acutely. This response was also demonstrated in vitro by the increased levels of anti-
donor antibody detectable in serum after skin-plus-peptide. The increase was larger and 
more sustained in animals that rejected acutely than in animals who survived for longer 
periods after their second donor-matched kidney transplant, and the antibody in these 
animals was found to be more cytotoxic. It is therefore clear that anti-donor antibody 
produced after skin-plus-peptide was sometimes lower in amount, in affinity, or in 
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potency than after peptide alone, and it was in these cases that long-term survival was 
possible. Animals that maintained higher levels of antibody or of cytotoxicity rejected 
almost as quickly as those receiving peptide alone. Moreover, the longest surviving 
kidneys were those with the best clinical appearance after reperfusion. Several questions 
persist regarding the effect of skin-plus-peptide on antibody. Therefore, the specific 
modulations in antibody level, specificity, and cytotoxicity after skin-plus-peptide are the 
subject of our current research and will be discussed in depth in the future. 
 
In conclusion, we describe a possible tolerogeneic role of skin grafts when placed on 
animals previously made tolerant to that donor. When placed several weeks after removal 
of the original renal graft, they do not accelerate the breaking of tolerance when a second 
donor-matched kidney is subsequently transplanted without immunosuppression, and 
they may in fact at least partially negate the immunogeneic effect of inoculation with 
donor-type class I peptide. The most likely mechanism is by expanding the previously 
existing Treg population preferentially to the alloreactive cell population through direct 
allopresentation. To our knowledge, this is the first report of skin acting in this manner. 
Future work will aim to repeat these findings with additional animals, explore the nature 
of the antibody produced, and further characterize the mechanism responsible for 
prolonged survival after skin grafting during the absence of antigen period. 
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VI. Figures 
 
 
 
 
Figure 1: MHC class I and class II haplotype combinations in MGH miniature 
swine. 
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Source: Okumi et al. Transplantation 85:270-280. 
 
Figure 2: Clinical course following second donor-matched kidney transplants 
without immunosuppression after absence of antigen period with and without skin 
grafts. 
Following second donor-matched kidney transplants without immunosuppression after a 
12 week absence of antigen period, 2 recipients survived long-term with stable renal 
function (after an early transient increase in one) (A). The same was found when donor-
type skin grafts were placed midway through the absence of antigen period (B). 
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Figure 3: In vitro responses of naïve pig to class Ic peptide immunization. 
After inoculation with class Ic peptide, the control pig had a robust MLR response to the 
PC14-3 peptide in a peptide proliferation assay (SI = stimulation index as described in 
Methods section) (A) and produced IgG against the peptide by around day 14 as 
measured by ELISA (OD = optical density) (B), but it did not produce antibody against 
SLA
gg
 cells (C). In part C, note that FPS refers to our negative control “fetal porcine 
serum,” and our positive control is serum from an animal sensitized against SLAgg cells. 
The vertical black line in the IgM and IgG rows is drawn through the peak levels in the 
histogram of the negative control samples and represents the baseline level of antibody. 
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PC14-3 peptide in a peptide proliferation assay (SI = stimulation index as described in 
Methods section) (A) and produced IgG against the peptide by around day 14 as 
measured by ELISA (OD = optical density) (B), but it did not produce antibody against 
SLA
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 cells (C). In part C, note that FPS refers to our negative control “fetal porcine 
serum,” and our positive control is serum from an animal sensitized against SLAgg cells. 
The vertical black line in the IgM and IgG rows is drawn through the peak levels in the 
histogram of the negative control samples and represents the baseline level of antibody. 
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Figure 4: CML and MLR results in naïve pig after class Ic peptide immunization. 
(A) After this naïve SLA
dd
 pig (17050) was inoculated with class Ic peptide alone, the 
MLR response to SLA
gg
 cells increased dramatically, especially when antigen was 
indirectly presented (bottom portion of figure).  This is consistent with the idea that the 
pig was sensitized on an indirect level since peptide can only be presented indirectly. (B) 
Although anti-donor MLR responses were increased after peptide, CML responses to 
donor cells did not increase after peptide inoculation. SI = stimulation index. %PSL = 
percent specific lysis. nDD = naïve SLA
dd
 pig. 3p = third party stimulator (SLA
hh
 in this 
case). For MLR data, self-type cells were SLA
dd
, donor-type cells were SLA
gg
, and third 
party cells were SLA
hh
 (which shares class IId with the donor and recipient but differs 
with both by having class Ia), SLA
cc
 (which differs from the recipient in both class I and 
II and shares class Ic with the SLA
gg
 donor), and Yukatan (Yuk, which are completely 
outbred pigs differing at all MHC loci). 
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Figure 4: CML and MLR results in naïve pig after class Ic peptide immunization. 
(A) After this naïve SLA
dd
 pig (17050) was inoculated with class Ic peptide alone, the 
MLR response to SLA
gg
 cells increased dramatically, especially when antigen was 
indirectly presented (bottom portion of figure).  This is consistent with the idea that the 
pig was sensitized on an indirect level since peptide can only be presented indirectly. (B) 
Although anti-donor MLR responses were increased after peptide, CML responses to 
donor cells did not increase after peptide inoculation. SI = stimulation index. %PSL = 
percent specific lysis. nDD = naïve SLA
dd
 pig. 3p = third party stimulator (SLA
hh
 in this 
case). For MLR data, self-type cells were SLA
dd
, donor-type cells were SLA
gg
, and third 
party cells were SLA
hh
 (which shares class IId with the donor and recipient but differs 
with both by having class Ia), SLA
cc
 (which differs from the recipient in both class I and 
II and shares class Ic with the SLA
gg
 donor), and Yukatan (Yuk, which are completely 
outbred pigs differing at all MHC loci). 
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Figure 5: MLR and CML results after injection of donor cells in a pig previously 
sensitized by class Ic peptide. 
After the sensitized control pig was injected with SLA
gg
 cells 64 days after peptide 
inoculation, anti-donor MLR responses increased even further (A), and now anti-donor 
CML responses also increased dramatically (B). SI = stimulation index. %PSL = percent 
specific lysis. nDD = naïve SLA
dd
 pig. 3p = third party stimulator (SLA
hh
 in this case). 
For MLR data, self-type cells were SLA
dd
, donor-type cells were SLA
gg
, and third party 
cells were SLA
hh
 (which shares class IId with the donor and recipient but differs with 
both by having class Ia), SLA
cc
 (which differs from the recipient in both class I and II and 
shares class Ic with the SLA
gg
 donor), and Yukatan (Yuk, which are completely outbred 
pigs differing at all MHC loci). 
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Figure 5: MLR and CML results after injection of donor cells in a pig previously 
sensitized by class Ic peptide. 
After the sensitized control pig was injected with SLA
gg
 cells 64 days after peptide 
inoculation, anti-donor MLR responses increased even further (A), and now anti-donor 
CML responses also increased dramatically (B). SI = stimulation index. %PSL = percent 
specific lysis. nDD = naïve SLA
dd
 pig. 3p = third party stimulator (SLA
hh
 in this case). 
For MLR data, self-type cells were SLA
dd
, donor-type cells were SLA
gg
, and third party 
cells were SLA
hh
 (which shares class IId with the donor and recipient but differs with 
both by having class Ia), SLA
cc
 (which differs from the recipient in both class I and II and 
shares class Ic with the SLA
gg
 donor), and Yukatan (Yuk, which are completely outbred 
pigs differing at all MHC loci). 
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Figure 6: Antibody FACS results after injection of donor cells in a pig previously 
sensitized by class Ic peptide. 
This figure represents the level of antibody in the serum of the recipient that binds to 
donor (SLA
gg
 cells) as determined by flow cytometry. After injection of SLA
gg
 cells, both 
anti-donor IgM and IgG were produced.  As IgG was produced as early as day 8, this 
represents a sensitized response due to the prior inoculation with class Ic peptide. FPS 
refers to our negative control “fetal porcine serum,” and our positive control is serum 
from an animal sensitized against SLA
gg
 cells. The vertical black line in the IgM and IgG 
rows is drawn through the peak levels in the histogram of the negative control samples 
and represents the baseline level of antibody. 
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
1
0
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
1
0
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
1
0
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
1
0
0
1
2
0
1
4
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
1
0
0
1
1
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
1
0
0
1
1
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
1
0
0
1
1
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
9
0
N
u
m
b
e
r
1 0 1 1 0 2 1 0 3 1 0 4
FL1- Height  - - >
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
8
0
N
u
m
b
e
r
IgG IgM FPS 
 
 
Pre 
 
 
 
Day 1 
 
 
 
Day 3 
 
 
 
Day 6 
 
 
Day 8 
 
 
Day 10 
 
 
 
Day 14 
 
 
 
 
Day 15 
 
Pos 
 67 
 
 
 
 
Figure 7: Clinical course and pathology after SLA
gg
 kidney transplant into pig 
previously sensitized with class Ic peptide immunization. 
Acute increase in creatinine and decrease in platelets following transplantation of SLA
gg
 
kidney with CyA treatment 21 days after immunization with class Ic peptide (A). This is 
consistent with accelerated acute humoral and cellular rejection as is the enlarged, 
hemorrhagic appearance of the graft upon necropsy (shown in hemisection on top and in 
whole form on bottom) (B). 
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Figure 8: Experimental Plan 
SLAgg  skin PLUS graft Class Ic 
peptide immunization 
Kidney graftectomy 
Kidney re-Tx 
No donor kidney antigens 
                      3 mo          3 mo+6 wks    3mo+12 wks SLA
gg(Ic/IId)  
→ SLAdd (Id/IId) 
KTx 
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Figure 9: Anti-donor CML responses at various timepoints (50:1 effector:target 
ratio) 
CML data showing anti-donor responses in 2 animals who accepted a 2
nd
 donor-matched 
kidney long-term after skin-plus-peptide (17944 and 18354) and 1 animal who rejected at 
day 12 (18351). Timepoints from left to right are 1) day of skin-plus-peptide, 2) 6 weeks 
after skin-plus-peptide (day of donor-matched kidney transplant without 
immunosuppression, and 3) after donor-matched kidney transplant. Anti-donor CML 
responses increased in all animals but returned to baseline after donor-matched 
transplantation only in animals that accepted their kidneys, demonstrating that skin-plus-
peptide did not break tolerance in these animals. Anti-third party responses remained 
normal (data not shown). PSL = percent specific lysis. KTx = kidney transplant. 
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Figure 10: Anti-donor MLR responses of long-term survivor at various timepoints. 
This figure shows representative bulk and indirect (stimulator APC-depleted) MLR 
responses of a long-term survivor against various SLA types after skin-plus-peptide and 
2
nd
 donor-matched kidney transplant without immunosuppression. In all animals, specific 
anti-donor bulk and indirect MLR responses increased after skin-plus-peptide. In both 
long-term survivors, indirect responses predominated initially (significance of this is 
unclear). Anti-donor responses became negligible after 2
nd
 donor-matched kidney 
transplantation in both long-term survivors. SI = stimulation index. KTx = kidney 
transplant. For MLR data, self-type cells were SLA
dd
, donor-type cells were SLA
gg
, and 
third party cells were SLA
hh
 (which shares class IId with the donor and recipient but 
differs with both by having class Ia), SLA
cc
 (which differs from the recipient in both class 
I and II and shares class Ic with the SLA
gg
 donor), and Yukatan (Yuk, which are 
completely outbred pigs differing at all MHC loci). 
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Figure 11: Postoperative survival in days after second donor-matched kidney 
transplant without immunosuppression in the five animals who received the skin-
plus-peptide regimen compared to the two animals who received peptide alone and 
the three animals who received skin alone. 
This illustrates the accelerated rejection in the two animals that received peptide alone 
contrasted with long-term survival in 2/3 of the skin-alone group and 2/5 of the skin-plus-
peptide group. One animal in the skin-plus-peptide group had slightly prolonged survival 
(12 days). Stars indicate animals that maintained long-term tolerance and were sacrificed 
due to the end of their experimental course. It is assumed that these four animals would 
have continued to survive indefinitely. 
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Figure 12: Creatinine levels after 2
nd
 donor-matched kidney transplants without 
immunosuppression. 
Creatinine levels in all 5 skin-plus-peptide animals after 2
nd
 donor-matched kidney 
transplantation without immunosuppression showing long-term stable kidney function in 
2 animals and slightly prolonged survival in another. In contrast, animals that received 
peptide alone rejected their 2
nd
 donor-matched kidneys between days 3 and 5. The two 
animals who survived longest (17944 and 18354) were sacrificed due to the end of their 
experimental course. It is assumed that they animals would have continued to survive 
indefinitely. 
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Figure 13: Gross appearance of kidney grafts at necropsy in long-term acceptor 
versus rejector. 
A) Picture of the second donor-matched kidney from a long-term acceptor (17944) at 
necropsy showing normal appearing kidney. 
B) Picture of the second donor-matched kidney from an animal that rejected within 
11 days (18351) at necropsy showing dark, hemorrhagic appearing kidney. 
A 
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Figure 14: Artistic representation of random polypeptide conformations versus 
native protein structure. 
Polypeptide sequences may exist in random conformations (A) or folded into a specific 
protein form (B). Antibodies recognize specific regions based on both amino acid 
sequence and conformation. Therefore, an antibody that binds the specific region 
(marked in green) in the protein (B) may not recognize the same sequence in a random 
polypeptide form (A). 
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